The technology is a method for determining the in vivo localization of double-strand breaks in a host cell using a linear polynucleotide.

The TNF-Related Apoptosis-Inducing Ligand (TRAIL) has been shown to be involved in apoptosis, cell survival, migration and proliferation. DKFZ inventors identified a multitude of genes encoding proteins that are associated with cell death induction by TRAIL. According to its individual function, inhibition or activation of the respective gene or gene product is assumed to have beneficial effects on cancer treatment. The technology can be used to screen for small molecules, antibodies or siRNAs that are capable of modulating TRAIL-induced cell death, thus having the potential to kill cancer cells or to sensitize cancer cells to established cancer drugs.

Currently, Multileaf Collimators (MLC) are established and state of the art in numerous devices for radiotherapy used for cancer treatment. However, the established MLC comprising 80 and more leafs require an enormous space at the level of the leaves together with corresponding drive elements and position measuring/ acquisi-tion. Since space is very limited within the head of linear accelerators DKFZ developed a smaller sized Compact MLC, which prototype was tested successfully.

Many light emitting entities routinely used, in cell biological settings show a dipole orientation. If the exact z position of the light emitting entity is unknown, using simple two-dimensional Gaussian fit algorithms to the light intensity distribution of a range of emitted light, may lead to calculation errors of the x- and y-position of several 10nm. The invention discloses a method for calculation of the exact spatial position and orientation of a light emitting in a sample.

Monoclonal Antibody against Neurofibromin as a diagnostic and prognostic Marker for Glioma Treatment. The proof of concept is established with Biopsy Material. The antibody is fast, reliable & ready to use.

Partial deficiency of Rspo3 leads to a significant increase of bone mass. These results indicate a major role for Rspo3 as a bone anabolic marker and/or target. Thus, Rspo3 antagonists are drug candidates for the treatment of osteopenia disorders, particularly in conditions associated with increased bone resorption.

The invention provides a long time culture model which can be used for the production of skin equivalents with a life span of at least 10 weeks.

To optimize the treatment plan for radiotherapy is time consuming and requires high memory and CPU. We developed the “Local Dose Shaping for Planning Treatment in Radiotherapy” as a method to simplify this process. The physician can use intuitive computer animation (i.e. “”dose lines can be moved by drag an drop””) to address individual local dose requirements.

The current invention provides a prophylactic HPV vaccine. Immunization against peptides from the HPV L2 protein gives a robust immune reaction that provides cross-protection against a variety of other high-risk HPV strains. Tha vaccine is based on a thioredoxin-L2 construct and can be produced in standard E. coli bacteria, which makes a cost-effective production feasible.

Rocaglamide makes tumour cells more susceptible to anti-proliferative agents while leaving normal cells unaffected. This allows dose reduction of apoptosis inducers and in parallel improves dramatically the patient’s condition during cancer treatment.

The invention provides a needle-based navigation system for CT-guided radiofrequency ablation of the liver. The key facts are: (1) Precise intervention and navigation aid for soft tissue surgery; (2) Real-time observation and supervision; (3) Inexpensive hardware/software equipment

Radiotherapy is a well-established method to treat certain tumor types in particular brain tumors. For fixation of the patient's head a “mask” is used, with is connected to the plate where the patient is located on. The novel technology describes a non-invasive procedure, where the patient mask is produced by rapid prototyping based on CT/MR data.

Specific inhibition of histone deacetylases by BMP4 efficiently restores aberrant signaling pathways and biological features in experimental neuroblastoma at nanomolar concentration without unfavorably targeting untransformed cells. In addition, recombinant manufactured BMP4 is already established for other indications (osteoporosis and type 2 diabetes), which should support the approval for this new indication.

The peptides identified by our inventors block the intracellular activity of the HPV16 E6 protein and thus increase sensitivity of tumor cells towards apoptosis. This effect is highly specific for HPV16-containing tumor cells.

Since cell culture contamination cannot be totally avoided, regular testing is a key factor for good cell culture management. The present invention provides means and methods to simultaneously detect up to 35 viral, microbial and inter-species contaminations. It facilitates sensitive and reliable determination of cell line purity. The technology is based on multiplex PCR and Luminex detection. Especially production units can profit from this cost-effective high-throughput method.

Method for the enrichment of diagnostic target molecules based on CD24 positive exosome purification, enabling the development of mainly cancer or fetal diagnostics and reducing false negative test results due to diluted diagnostic target molecules.